TABLE 1.
Patient characteristics
| Phase | Case no. | Sex | Age | HBeAg/anti-HBe | HBV DNA (log IU/mL) | HBsAg (log IU/mL) | ALT (IU/L) | AST (IU/L) | Metavir activity stage (/3) | Metavir fibrosis stage (/4) |
|---|---|---|---|---|---|---|---|---|---|---|
| Immune-tolerant | Pt.1 | F | 19 | +/− | 7.05 | 4.46 | 33 | 28 | 2 | 2 |
| Pt.2 | M | 33 | +/− | 8.23 | 4.81 | 27 | 22 | 1 | 1 | |
| Pt.3 | F | 41 | +/− | 7.26 | — | 17 | 20 | 2 | 1 | |
| Pt.4 | F | 42 | +/− | 6.44 | 5.10 | 24 | 22 | 2 | 2 | |
| Pt.5 | M | 40 | +/− | 7.71 | 5.20 | 19 | 19 | 2 | 1 | |
| Pt.6 | M | 28 | +/− | 7.78 | 4.79 | 19 | 23 | 0 | 0 | |
| Pt.7 | M | 23 | +/− | 7.79 | 4.78 | 19 | 17 | 1 | 1 | |
| HBeAg (+) IA | Pt.8 | F | 26 | +/− | 6.08 | 3.03 | 62 | 57 | 3 | 2 |
| Pt.9 | F | 41 | +/− | 5.56 | 3.26 | 113 | 64 | 3 | 2 | |
| Pt.10 | M | 32 | +/− | 5.32 | 3.78 | 46 | 35 | 1 | 4 | |
| Pt.11 | F | 48 | +/− | 8.10 | 3.79 | 75 | 59 | 3 | 4 | |
| Pt.12 | M | 36 | +/− | 8.23 | 4.57 | 301 | 231 | 3 | 4 | |
| Pt.13 | M | 51 | +/− | 5.06 | — | 41 | 53 | 3 | 4 | |
| Pt.14 | M | 43 | +/− | 4.67 | — | 20 | 29 | 3 | 3 | |
| Pt.15 | M | 46 | +/− | 4.90 | 0.08 | 49 | 33 | 3 | 3 | |
| Pt.16 | M | 39 | +/− | 4.70 | 3.67 | 33 | 24 | 2 | 4 | |
| Pt.17 | M | 45 | +/− | 5.13 | 3.41 | 94 | 68 | 3 | 3 | |
| Pt.18 | F | 40 | +/− | 5.51 | 4.49 | 46 | 45 | 2 | 1 | |
| Pt.19 | F | 35 | +/− | 7.29 | — | 33 | 32 | 3 | 2 | |
| Pt.20 | M | 28 | +/− | 7.12 | 3.86 | 96 | 63 | 2 | 2 | |
| Pt.21 | M | 33 | +/− | 6.95 | 3.91 | 104 | 39 | 2 | 1 | |
| Pt.22 | M | 27 | +/− | 7.89 | 3.95 | 394 | 156 | 1 | 0 | |
| Pt.23 | M | 37 | +/− | 4.62 | — | 22 | 23 | 1 | 1 | |
| Inactive chronic hepatitis B | Pt.24 | F | 34 | −/+ | TND | 3.00 | 16 | 19 | 1 | 2 |
| Pt.25 | M | 36 | −/+ | 2.34 | 3.25 | 24 | 17 | 1 | 2 | |
| Pt.26 | M | 31 | −/+ | TND | 3.54 | 21 | 24 | 1 | 4 | |
| Pt.27 | M | 36 | −/+ | 2.54 | 1.77 | 112 | 58 | 1 | 1 | |
| Pt.28 | M | 51 | −/+ | 2.16 | 3.47 | 33 | 31 | 2 | 4 | |
| Pt.29 | M | 52 | −/+ | 2.61 | 1.73 | 55 | 40 | 1 | 2 | |
| Pt.30 | M | 38 | −/+ | — | 1.47 | — | — | 1 | 1 | |
| HBeAg (−) IA | Pt.31 | M | 55 | −/+ | 4.77 | 2.43 | 245 | 132 | 3 | 4 |
| Pt.32 | M | 45 | −/+ | 5.06 | 2.72 | 103 | 152 | 3 | 3 | |
| Pt.33 | M | 30 | −/+ | 5.30 | 2.82 | 399 | 110 | 3 | 3 | |
| Pt.34 | M | 48 | −/+ | 6.08 | 3.69 | 67 | 56 | 2 | 4 | |
| Pt.35 | M | 37 | −/+ | 4.38 | 3.77 | 37 | 19 | 2 | 3 | |
| Pt.36 | M | 38 | −/+ | 7.52 | 4.21 | 79 | 57 | 2 | 3 | |
| Pt.37 | M | 56 | −/+ | TND | — | 31 | 29 | 3 | 3 | |
| Pt.38 | M | 43 | −/+ | 6.04 | — | 39 | 32 | 3 | 2 | |
| Pt.39 | M | 32 | −/+ | 3.77 | — | 28 | 59 | 2 | 3 | |
| Pt.40 | M | 44 | −/+ | 5.36 | 3.33 | 55 | 28 | 2 | 2 | |
| Pt.41 | M | 46 | −/+ | 4.33 | 3.41 | 26 | 22 | 2 | 4 | |
| Pt.42 | M | 41 | −/+ | TND | — | 31 | 20 | 1 | 1 | |
| Pt.43 | M | 40 | −/+ | 3.50 | 0.91 | 102 | 130 | 1 | 4 | |
| Pt.44 | M | 51 | −/+ | 5.58 | 3.26 | 26 | 25 | 2 | 4 | |
| Pt.45 | M | 37 | −/+ | TND | 2.93 | 41 | 33 | 3 | 4 | |
| Pt.46 | M | 56 | −/+ | 5.09 | 3.59 | 40 | 34 | 1 | 2 | |
| Pt.47 | M | 35 | −/+ | 3.74 | 3.60 | 19 | 23 | 1 | 2 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; F, female; IA, immune-active; M, male; —, not available; Pt., patient; TND, target not detected.